0001193125-24-219608.txt : 20240916 0001193125-24-219608.hdr.sgml : 20240916 20240916161556 ACCESSION NUMBER: 0001193125-24-219608 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240910 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240916 DATE AS OF CHANGE: 20240916 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bellevue Life Sciences Acquisition Corp. CENTRAL INDEX KEY: 0001840425 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 845052822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41390 FILM NUMBER: 241301228 BUSINESS ADDRESS: STREET 1: 10900 NE 4TH STREET, SUITE 2300 CITY: BELLEVUE STATE: WA ZIP: 98004 BUSINESS PHONE: 425-635-7700 MAIL ADDRESS: STREET 1: 10900 NE 4TH STREET, SUITE 2300 CITY: BELLEVUE STATE: WA ZIP: 98004 8-K 1 d894292d8k.htm 8-K 8-K
false 0001840425 0001840425 2024-09-10 2024-09-10 0001840425 blacu:UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member 2024-09-10 2024-09-10 0001840425 us-gaap:CommonStockMember 2024-09-10 2024-09-10 0001840425 blacu:RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member 2024-09-10 2024-09-10 0001840425 blacu:RightToReceiveOnetenth110OfOneShareOfCommonStockMember 2024-09-10 2024-09-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2024

 

 

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-41390   84-5052822
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

10900 NE 4th Street, Suite 2300, Bellevue, WA   98004
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code (425) 635-7700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Units, each consisting of one share of common stock, one redeemable warrant and one right   BLACU   The Nasdaq Stock Market LLC
Common stock, par value $0.0001 per share   BLAC   The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share   BLACW   The Nasdaq Stock Market LLC
Right to receive one-tenth (1/10) of one share of common stock   BLACR   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01. Other Events.

On September 10, 2024, $50,000 was deposited in the trust account in connection with the extension of the date by which the Company must consummate a business combination.

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 16, 2024

 

BELLEVUE LIFE SCIENCES ACQUISITION CORP.
By:  

/s/ Kuk Hyoun Hwang

  Name: Kuk Hyoun Hwang
  Title: Chief Executive Officer
 EX-101.SCH 2 blacu-20240910.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 3 blacu-20240910_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 blacu-20240910_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member] Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member] Common Stock [Member] Common Stock [Member] Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member] Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member] Right To Receive Onetenth 110 Of One Share Of Common Stock [Member] Right To Receive Onetenth 110 Of One Share Of Common Stock [Member] EX-101.PRE 5 blacu-20240910_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Document and Entity Information
Sep. 10, 2024
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001840425
Document Type 8-K
Document Period End Date Sep. 10, 2024
Entity Registrant Name BELLEVUE LIFE SCIENCES ACQUISITION CORP.
Entity Incorporation State Country Code DE
Entity File Number 001-41390
Entity Tax Identification Number 84-5052822
Entity Address, Address Line One 10900 NE 4th Street
Entity Address, Address Line Two Suite 2300
Entity Address, City or Town Bellevue
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98004
City Area Code (425)
Local Phone Number 635-7700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Units, each consisting of one share of common stock, one redeemable warrant and one right
Trading Symbol BLACU
Security Exchange Name NASDAQ
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol BLAC
Security Exchange Name NASDAQ
Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share
Trading Symbol BLACW
Security Exchange Name NASDAQ
Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Right to receive one-tenth (1/10) of one share of common stock
Trading Symbol BLACR
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /N!,%D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #[@3!98F7>GN\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$[7PDR:RT9/'0Q6V-C-V&IK&L?&UDCZ]G.R-F5L#["CI=^? M/H%J':3V$5^B#QC)8KH;7-LEJ<.:'8F"!$CZB$ZE,B>ZW-S[Z!3E9SQ 4/JD M#@@5YRMP2,HH4C "BS 365,;+75$13Y>\$;/^/ 9VPEF-&"+#CM*($H!K!DG MAO/0UG #C##"Z-)W &UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #[@3!99@?%23(& !>'@ & 'AL+W=O](+'7*."CIG$Z:OB[&$HW:EDO",Y8J+G$@V.V[U M_8\G46@&V"N^\$0OCEO=%DG8C"Y3?256_[#-#76,7BQ2 M9?^2U>9:KT7BI=(BVPP&@HSGY7^ZWDS$-@."S8# $9RP8H_XW@X)O"#Z>7@;V"K H (,K%[8!-BO!23?SF$ &6F6 MJ?_J:$OUJ%[=K/F/JJ Q.V[!HE9,WK%6[\\__'WO+X0]K-A#3+W7!_#$PI^E M=%Y'AX^?T50QA".J.")49S-M R"1-(7I2]B:?&+W=42XDN=Y?C?RHJ"#8'4J MK XJ5H5V>E^P.A9\>'?W$P*Q7T'L;PD?5&@' MVX3MBLVY@L !XP7-:L%PG9/A^?GPZ_60G(_.AF0R& TO!L,)Z0^^7(\FH^GH M\H(,+J_&>PARMT+N;H,\RF,A"R'+%)UHF$\R$$M8?K *15)[#[CPZ1"A.ZSH M#K>A.^,I(Q?+[);).A!< Q)@-_+#0P_A\3U7?;UMB*9T348)K$(^XW$Y:<_S M-4AVH]V.UPFZ08 1/O('?QO"?I) ?50[#Q^(+;N7>6TH&R1][]#SR,601'H! MBT."=V&HSBE\M)CCJ-.5J$7%)2=+#DLW"#TTW,X/?+R@_THX,$="DJE8U5LM M+@=-5=/'T)Q/^'BE_Q5M+)0& M'_N7%\]6DP;%PZ[G827:=_;AXU7?AK /#?'S*+C >S#3#QB*LPL?K_/G(H99 M&2]$CI6W!I']L+-[<("O=^<&/EZU;R37FN4P-5FVS#>E3=52X4)-G9#O+,#' MZ_=$I#SFFN=S\AD6N.0TK>7!59IX N< 5ZNQY+9Z6&0864S!#TCD^1R-JN/ M7X->(YFK_ %>II^0C91: EDC("[;"/AH9[!5O1]F3,Y-//\&!7 48"YH7MO< M-@AJB=;2P-7Y8*LZ/UR3*?1MBEM'+QO,6JS?VP8$KL8'>#V^SKE69$AC,TO MI6P>7,Z,D9/)@D+$X< $W;9M(OYNSURQA+&,WD+;=$.E[43-;LR>,KM>$I!O MGYDI./5;,!3JA7NPP+E'T'G;'21J)2_%=P83-&TKXJ4TS'YP2Z9O.DP)XRH<=NT1E7@'L. M)$EB<";WV:VH+<<- B?G_<$UAN(<*\"-IIKMX3I>T'S.GMUS-0A=]">G_2\8 MD[.L #>;G_(13314YZ4/.YR5A=Z;)EJ(.MM+\9W?A;@Q;9=H#2*#GS*HH)+< MT73)R#MOSSP[(04XITTW#-DY8(@;5G/B- B8Q,%('CWIPCUJ^[QI$&K,F]"Y M78B[W5/; N];,QES9;\\@\V--3WUQ/7Z9A$_7,Q@"\1C:XV^O]?QC)-OW-)' M\Q'G>^F"=L87OJWQA6]A?*$SOO UC*]!Y.J)?QD;?+0(8#K*A%2_&B"AQNL> M+F:DL(L +GI7KH*M4MEY8/B['M@@8%+Y!D-Q'AB^E@,WM8QH[=PS,@Y9O0:CMD@4D96 M"V@UR\A";[E;AO:]W_:]#VB7BMV'L]'H=VVT0<#DWA6&XGPT>BT?;1!Z/O?: MC]X6FC>OGZG9/BN2LADH>7L'4/9E^3*S/-"BL"\0;X76(K,?%XPF3)H+X/Q, M"/UP8-Y)5J^4>_\#4$L#!!0 ( /N!,%F?H!OPL0( .(, - >&PO M9KEMWDOSAR+DCO9*ZW="C<\W[)&D/ M1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O M:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\" MO @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9 MY=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL) MBS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W M3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y M]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5T MR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00, MX[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/ M+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^ M>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( /N!,%F7BKL

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 5 24 1 false 4 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports blacu-20240910.xsd blacu-20240910_def.xml blacu-20240910_lab.xml blacu-20240910_pre.xml d894292d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d894292d8k.htm": { "nsprefix": "blacu", "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240910", "dts": { "schema": { "local": [ "blacu-20240910.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "definitionLink": { "local": [ "blacu-20240910_def.xml" ] }, "labelLink": { "local": [ "blacu-20240910_lab.xml" ] }, "presentationLink": { "local": [ "blacu-20240910_pre.xml" ] }, "inline": { "local": [ "d894292d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 3, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 5, "entityCount": 1, "segmentCount": 4, "elementCount": 33, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 33 }, "report": { "R1": { "role": "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-09-10_to_2024-09-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d894292d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-09-10_to_2024-09-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d894292d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "blacu_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240910", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "blacu_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240910", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "blacu_RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member": { "xbrltype": "domainItemType", "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240910", "localname": "RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]", "terseLabel": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]" } } }, "auth_ref": [] }, "blacu_RightToReceiveOnetenth110OfOneShareOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240910", "localname": "RightToReceiveOnetenth110OfOneShareOfCommonStockMember", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]", "terseLabel": "Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "blacu_UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member": { "xbrltype": "domainItemType", "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240910", "localname": "UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]", "terseLabel": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://BellevueLifeSciencesAcquisitionCorp.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-24-219608-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-219608-xbrl.zip M4$L#!!0 ( /N!,%FK,_OSB 0 #X3 2 8FQA8W4M,C R-# Y,3 N M>'-DS5?;;MLX$'TOT'_@ZFD76%F2TVQA(4Z1YE($R V.L[MO 4V-;:(4J9)4 M+G^_0TIRY$MD)!,K2U,&D7W]_>=;,RE4:*T:,%TF,HC$H:- M_N'PAOQ=64_) 10 R2GQH(FGTLNLK0;=W>2..EVNFV8!NKLD8Q:2$DO2CY& MJ/B!)-TT_IC&'\C!.3GV9B09\AS:6%4\:CZ96O([^X-XU)&2$H2 1W+")96, M4T&NFY#_)*>2=.="#O%8OZA!1%4%BO3[ 1/A*FUFH]*"R=*YT8WWYJJN%]A4\S0+85)-]Q).F@L('*)S)I.(-&K VEZ9*M M9@VV<2#FN8W@/D+W\9SWU=MGZPPLS@O'O^?X)W]MQ']IWKQ!)$I>O#:8UM#< MOB:2MX<1J]G/3**16!L*9964M_]9![ZS#\ M*;5Q'*TSK0[$AT&E5-;[;@='BX++L:J7<-%MZK39V0,8$W\JI%0SK02L/SNB M0JL"M.7H_VDX5 :F&L;]P!^M83-X;P4==7#P-CI+'N;GC1-'" %Q]A1?@[7< M.O"9$Q,GQ]L)%3/3+BG]P& M1&M>_=]\"PTOY8L0@\>@+]SSM*]:6K\L^PS& M+V6/$"[Y>NY',YT7,W<^AJA!W,?-X/3%5XC9'2*R]$%)E3]6<1\I5KK;2_/_ M0&;'$N-]/,7-IG-?IX!PO&P,4/UV(_59[$WT3\G93V+WA\^+QD+[D\J,5.9( MR]Y>M&ADT7YI(+N4^_Z;4<%*,>O"&EQKK ,N]N_FR/G:K\;5JTT=F\D6+8ZV M>F5^!/H!6%\S?2U\O]ZN*\*0CEP?N0&,C?=]Q:K]_-T^-7CKE9-3"[D+-2"F M'!E$^:?4%ZW*HE+,;#I%N6;E")PR=K*'XQ)7V= ;S$I=MY#D0CA7_<#J$HU2 MM*DIL\WO:%NFF'/OWFS"MJ6\!6.>\A_+\P;;R!Q3-CW$1RO'$.3D*WEM%?N*BP/( ]J]/4/U9IZPF[9/7"[YY"/0#7N[5?:J%W*: MJ9QR^?/3MQ2Y.7[ _N3&+>'[S-,U)G^F#=_!@ *CP !8 !B;&%C=2TR,#(T,#DQ,%]D968N>&UL MW5M1;R(W$'ZOU/^PI2^MU&592"X-"CUQA%2HR1$!UZOZ$IE= ]9Y;6I[$_CW M'9MU F$ANX2]NZP4*:SQC+]O/![/SHB+]XN(.O=82,)9J^)7:Q4'LX"'A$U; ME5BZ2 :$5-[_\>,/%S^YKG-YU?OHN,Y,J;EL>M[#PT,UG! F.8T5:)#5@$>> MX[IV?F?TR?E[I;WI###%2&(G0E)AX7R("0V;]5J]X=?\>K6^+B8PTOJ<$"G< M=,X]_\R#B2>.7V_6SN#/:=\X7:.&.2,2X759/E\*,ITIYY?@5\=(77+&,*5X MZ5P1AEA $'6&%O)O3H\%5:=-J3/08A)P2BSN<5A-M%+"OHPU<+ 5DZV*9I^0 M7XP%K7(Q!72UAFIEG/<8!@+"!&!>WZ^>UF[Q:K:?=^^*Q'"H6;0KC/@ !YC<8_ -N 35S/=K.YPJ-^4# M]>=P2HF#ZI3?>R$F*W^$#T]N" ]W;8BOH8ZQ5Q1-LV!/$3HJH-6EU0'E M$> M9!V+O_ R*[ =PD<%:"_8$6#)BFM3IA XX/6$PY4?7L*EF1?7,^$"-G2 IQ"1 M]<'^B*+,^-)E"X#78P'DJ5R8-,GD'1T>@Q+61+?,KTA[Q$^ M*L AIR0@^D7J!AQ;$$2SHDN3/"JT6X$U=5UN,IF5+E")_F22?7/W:2@2:D_* M&(O7 T[1<]S-QT$,/K;TZ^,14=F*9>ER1X4U$DCWT(;+:,PSN^,SH4+LU%T$ M,\2F.$^"FRY;P*W1C;"8@@7^%/Q!S<"-YHCE?*W:H:((L O8+[:J'Z]>37(B M39%_A/E4YVZ+8$,M$H%5F70',C:W5C(3P:.<5=AD=9ZCRLP%'/=6!1++.1#3 MOM.J0/(62P#+YWJB"=*F3=(,.%-XH;K4!(Q61>*I_O#T/>42AZV*$C$NS$2I M'99\)MLLUO-,)>)LABJ(\W:C;IUP]BHYWU]53CC6&]^:I.V<%L!2EZ(?>59K MM=HWVM'-EF8:T3U%>%Y?4[C'JOH+FC3)_0;=1*1G>S^F]9GI24Y;->@J5[6C*Z MZ:T)R_9=*=F^T-JPY,]*27Z]6V*9_EY*ICM[+I9V.>^CU.Y-0OFD;'?2GCZ0 MI>R7F?)Z3\D2KI>9\%9KRK)NE)GULQZ7Y5RVW&NS=699EBWEVN[&6:9E2[=V M]/8LW;(E6&G-0LNU;"G6OJZCY5RV_.KEQF7"_+1L:=9V+]0R+5MV]:S#:FF6 M+:=*;]A:MN7,I78T?BWILB53NWO(EG'FQ.K"_(SSV4^K] ]?'W_>"0__ U!+ M P04 " #[@3!9IR4#300) ";9@ %@ &)L86-U+3(P,C0P.3$P7VQA M8BYX;6S-75UOVS@6?1]@_L-=S\L,,/Y,%X,$30?>? R"29L@<7<66RP*6:9M M8F0Q(.7$_O=+4E(LQY1,F9>1']HZTN6YYS#GDM>RY'[\?;6(X)EP05E\WNIW M>BT@<<@F-)Z=MY:B'8B0TA:()(@G0<1BP,_A+Z!'7;(X)E%$UG!-XR .:1#!8T[Y5[B)PPX, MHP@>U# A>0K"G\FDDZ%&-/[[3/TU5NSAQQ\ Y#3&0A\[;ZG)R.9B->91A_&9 M)-L[Z>9#6IL1JYTA+R=Z0/_T]+2KSQ:C!37%2O!^]S^?;Q_#.5D$;3G]\M<5 M9FD$/1/Z^"T+]1Q:$(32"/53.P]KJT/M_J!]TN^LQ*3U227,9B<8D^A6O@*M MX8RSB%0D5J=U]E86GZR?9#Q9)22>D SY%9N%6=2YCCRY1[]640W9/+W]I2T-6(^?,K9PL@B2\<,)[]'X\A(4SE)OE+E3>+V MU\=]6E.@HC!.!%MR::\ZOUJMYY-&AF\Y]O\^=C>YCX6J7$($N:W+U\V2PX6T MN?R37$?!S-:2;P8U9$DS=68XZ6)) Q"2)5^104$[&](#T:(A;=FZV?$J3FBR MOI!I>!#=R 5X]2=9V]JR9'!#]JR6PBJ"7.Q: 8ADVS0#9"E YP"9Q-G 'JD7 MC5R?OYNE+UFX5'4SDNQMG;P]IB$#&XFSW7,N=MW%07)I#@P*V=F:^#2+CK3D MBF/#>\(IFUS%DTOY?J:N']\,;MB89BFL(@C#J@9 ;,^F*4#F )4$S;X>J!M] M;,T?HUEX(#.JFN0X^1(LK!UM'MMHJU BA)7'N#<*)CS ]6HS>UD,NLA[D5@ 8]; M$UL)06>$+"6HG$A%\@ZZ##5SN#B,(KJF$?FR7(P)KU*](81AT%JYN););HE*87QP]Q;2E(HQ;>)XU9!+N; MNQ(8U^DR%6SGPO6]5RF&(CA #T9)#"<3*4!D_]S2F/3KE8,1H-%2J)+$]@2Z MET I**[],_Q?\Q>@,L%=C-7'>)-AL/X!6OQ8?^!J_<'167]@:_V!#^L/WL_Z MHQ?FS?I(,JRM7ZD%T?H7\N4='[&7^"#C%X0DJ&/X[3%-W0%H(LYVSSG=_[>#@V1< MO<\K9!R?XO/?98=-Z=!9.MET\B&C%PA@I5%N%BX M# W)OQMXR/&=S>N+$U4?1-I"WPFIGH[A=].I?>-0A="0C2U$ ML7V1+K;>AXID;YD&BGD@300ZD[/1?8LH&OY ):C6OQ%B2;A[ 1APCJ,,R@6: MBV$G'K$D2K!]%4::SFM]>%)4626U9#FV-R1F!:-&2MFQQULVK53B7:DF=AQG,8QM>/XU" M6'D,QCJZBX>]EN89( M!557$],GXFKZWS"^6?.7"V+5<0BV+\%$]OP*-FFRQQBQ#.])@,GMM52\L?HX M"L*ELO.'WFF_IRVM#[T^1#J,)_GC15/&%_IB^2@8V[W3LX9JP.AU93+K(8?: MOQ8\4B6\/L0KT\'K(UVO">&;3NGV_3GOJLOXA/*AXC"*Y9;&Y"8A"ZO/,&O! M'671[,JU*IS78?Z*YTV*]RH@E19T7M]5A"RP5B59J:QJLZ:!&&L"2]&>!<%3 MVFN1*!'YD4W3E1WXKF]B5+0NHD"(N^ECPL*_ARMJ56H6( T4F+TT9A%\:#%9 M B.5D 8'-@4-#]]4 K=:>2?^6W=QU1.!70I%@9=L$5"KYRJJ1C=H_@HQK"K* MU>YEB)Y\GJ; <;HOZE46W\O?MGWZ&M-$7 7A_(+)MS%"W>!P-[V+R>,\X.1N MJC[;4M]H()/*@P]D0LA"-6Y_!5Q]5X?@[]&8Z[5>IBL%-[L^E4EA%D//N; ;$VIR+)D(I,L^\ MM[\^N!9YVWUYI^;%U8KPD IUZ)IQ78%B:Z48RG4A"R+WG(9R'>GW.__LW9,T MNE]WA_;)H;&]^ATFEOG/Y;9_^^:%M"[L[B5R0]H0! M9J-XX%:^D@?S0S3]GT7DD?\#4$L#!!0 ( /N!,%D3ZQ>A/P8 +A 6 M 8FQA8W4M,C R-# Y,3!?<')E+GAM;-V;WW/:.!#'WSO3_T'G>[F;.3 V M27-AFG8H26Z82TH&Z/7F7C)"7H.FMD0ED$39^,R;R1J6A%(/2859A!/.X,Q;@/3> MOGGYXO4OM1HZO^R^1S4T46HJ6[Y_?W]?CV+*)$]F2KN4=<)3']5JMG]G^ '] MLQRNA?J0 ): 4BP5"/1N1I.H%3;"9M (PGJX:B8 &W\HP@I:Z-0/3GS=\0@% M8:MQTFH,09+ EU2AAFA.$$# M&_(?J,M(';63!/6-F=1Q2A!W$-5SKPEEGUKFW\A$CUZ^0/I/)Y+)K/7,,^G( MLS$?B:3.Q5B'VVCZULA;M9EO&=TW,Y/@]/34S[Y=[R]I46\]0.#_>WTU(!-( M<4U#T-#(QE ZFDA]L5X-[MA??FG[2]J2F:/_2[7\9\9W#=S>"*QC @5-R7+,I.DT 0_Y*SJG0M<44UGO*]VP9@!S M!2R"R+HQ"GYL)MXLBR"O=$[6,F,/]HRP!%(?\SL_ FI&;)HW)FO-+&/ZPVV' MZ_FE/9)*8*+6,Y.8TN+"-B9X!,F95V#D[PVH %76=+M/XQ"/#)2'PRGM:CW( M5<)M0=8&PH+80?3;-;S;AT[>PY]BH?W5R$3/DM8Z%CPM3%@^&J\0/A<1B#,O M##PT%90+W4E_\M!,ZNCXU/3$B?D.8A "HJME>G;&G06M)V0)6<\G@:@/'>@J M2.7W ;GB[ME@5JW<4HA7A%G,X?-@7IL\8BQ'F2=]I3'&>+J<02!1TK9\G4KR MAMN!I@!&9R?!4O;B@>+D4WM.2Y5 "2%73.4TQ9%@\%$YZ07=WB:0SH"47Y.__XC/WN5["E\_G2R;6D=N3I= M?)5R)W)(\/K!)8JL,Y<4MB[5O!/<"$IT M:0=!_;AQ \O>0=7IXBEC./"*>?H$V,)[=6B%9R:Z(>\# 7H'>N;3:VPU"8+& MCBFSXP=A'D#BDYT&;#&:!6_5 G MN"S'=1L7\:TKL-2.G*.FKPDHU[JC<[W2K8IOP]AECAM2+-!C9X N)?=A3,V^ M,E/O<5J:9[&MBSB+E5B:KQRCV66$BRD7F>9L+ZK#9_J$L>CPJ"+V+([TO]8+G7W'FPJV(LUM!-K-G%8$_<"'Y'SX] M3FXFG%5RWYS,$P>B%\?E M)]E]'ESDND^/Y>O./M*&FJZ4,Q#?3KG ST_ ND!53OS8G#13KBI4^K&T8NLMN08,&YLT=DB^]B3B:8 MC:'*#^7%MBYB+%9B:;JV%W21@ACKJOQ+\'LUT6>+*685;RK;X<)%MGL%6<3N M; ?E7-^M4Y%M@[S#< C66[ _8,GKM;V5,!_S)/'"__,;\,X^/ MZY;_ 5!+ P04 " #[@3!9S,V;^$4/ #(; #@ &0X.30R.3)D.&LN M:'1M[1UK<^(X\GM^A8K=O4VJ MA 'A#"%<,PN]QF0@XR-UOW94K8(JC&6%Y) M!+A??]VR#>85" 0F,YNIVAUL/;K5+W6WVIKR/T=]CSPRJ;CPKW^U,]:OA/F. M<+G_[$XT8>][_.#!OFS2"[6"QF36O<=:'G!$#.LO)9;.Y0Q>+N'8\Z@TG_ M=\SSV.. W? N:SLR? M'V_:3H_U:9K[2E.8?=LUJ27W5%;)/D1(XTUG:RJ5SYXE)TB F,Q/%8K-NGLMTWI[0 M$H#SIY8Z1T5L=>?$->I\G@T;$]+Z0&FP5%BQ(2FKJZ4-]22%^L*H"W]IKCU6 MN4S_4%I!K+S>)VJ"5\S7Z?O0;Y3Q F?KE.:C7363)>%4=EP M0D)(N2/<<:7L\D>B]-ACURF7J\"C8U0@EJJ0,A^5L#>3T6_NNLP/?T.7VU![ MB$_[.);Q4K7/?!?^TQ\\^A!A,-(MUH7F@32L^()"G;:*:=OZHD7B*46X>YWB MH\=T+E=(5;K44ZRQ$4:E1C(\-%H62FBKV'7!O2- MAS'#K%;P;!RQ9S&0AIQV.?J01+JJN^ MBZ_Y0T_G/K)^A\D#L"FB-7O 947/+L ;!1YWN [Q("Z'9N-SI"):E%;2(E4Q MQ"B]-#'*V:6X37D\7<3?2_;B'@F*?M?B$W=96,^;!#QI?19T2-5'3#I/^5:*OQ[KZJD_E _?3^+M$Z$"+^(U$XH>O<+H@G@SC MU72/F58[8P63*;0(2HG'CM!:],V;CI" >OS&#D9$"8^[Y"?+_$E5_O&3?6Y= ME;/!*D#Y]8!R6P-*3%N 2+6'/I]O&??T]:=]7[^OMU>A8!T*G7:]]:C7N&_4VJ=Z^ M)_4_:[]7;W^KDUKSX\=&N]UHWNZ$8^XE=;26;&@FZSPGD5:FG._F5Q]1MJZ70QL9%8QK"0'0>0 MJ@_-UD=25@'U)X:HQS5+PQN'E7PQE#1(559F9MX+9X!V.I$:VB(Q(D6I,T<%,"0 M8G:>-%O$/CMV3[X]EJ)+[GL,$1Q(KCF,KX^<'O4?&*DZFD"S7;,O+V]?-#W72KC7JMS5TMFK__M1H M@^/5O 5?JW6769*=W\&@6"]!IN/ZB(+A0!J$ZAI3A5!%V@%S, YT"?=)#0(R M&#)O!-^$?H70[T*8H[+&A MQF.>A/X4GUBF0.GP.J.O&SQ&H:*F.\#P:*%:* M?SPM'@E90H&12.9]PE4.#U? =(6&W-);))%=J8N!K M.:X)=Z?M$$^O,=6A62#%(X*=V0\O(+!^SSPZA'URI9^MW4VX/Q'Q^>Y[(>?6 MH4E([P_<8]"&6;:M-X<+&_-K=KI@YXO62N+]N#2\IZ-&E$QT#-%V)F@.XKU" M^LPZRUWF88,[9. M9J/5)O5^X(DQYI1_ ($![VUFBSAYS>1'XTI"8_"J\9RU7N169$X6A 7^A\[: M]^K[F3AB%^?OS'H1]ZUP^7K=MUCT=O/@JJXKF5+17S<0TM@[[(3Y5,6VBI9% M;NNDH'NDK25C>GY+/%T7!R\BE=L!J4*JTAZ FT!R>6O!X=D4EQK\;,I[,?1W MP.0,PO*HJG5;/,P.W)1WX!5S4WBY-3+GJ"O+ILM8% VU2%;CO*]B50KY [.UG,"&X=<=T(X-X=KFSG(*N8JISG MS](7%XLV?/G)VK?@[:W0I!I@#0A*VBZ9U!R:#=^L(\%G,LM:LK,-GBLE P\VI T0(TD< M$B0.SEL#$!?8UR)1U;-'U7A"?6Q?D-J'%L8'F7 ###8-I=_D=[W\MH6IB02X M'\&0@37S]B>\]O=B(S\5\IDBC%C$U\Z6*UB9 M<,:3A%OUI@TOI@UWDJ$EQT_!3*D9;L02(JLMG..-M2+W/6G%6A$%"J:=! EC MT5^W!VR@26XZ=]PY>5E="N=\TZ9#:%-#J0&3!]&I_)M.;:13>98N'#N;ZI11 MF3SX:S!DO1_VXJ%7PC$,8QPF(4H*5I9AHF;'@0\L8W6<\SZ1[O4@@K99T> M]Z';L3KY82BVCTQE7.MI!(Q%.\.S\J?[X*/P">@B8#3=#&;WI%=W*+PF$@^W MM[&=ZQB5?J9W].VN44CX7854Q4Q_&AFC"004'SQ"40@$'QP#!B@)<$Y-DYR M(L,0%J&^&S8AN&=[^0=GG_?5&N?7CF=8S6)/=0MBO&_ M(;GG(QBTI@L%M)?GL$N!TWI+E4O_(@8 ^4CE5Z;)S4UM*8/>+-[S+N](4/LB M5:G-6*. 2O)(O0$C/UL9_-J=!/A9?&]I/?.K4HX]&Z&-R'D9VI%73JG#F)$G M"+:9)2B^68+OY!*7*=.*%M:1S#LSZ!--82'[0XNBYKTA0M'QB3LS$B!0[/2S M@?MFBP[/4#LT:9]?.<4/Z1KMD_ ;F<9B[LTTOH+[A"8,L?&[5C,)9F)E.,WZ M%#2$=VD#*$%%'ERC-)T<66J?.+. 9X'N WY%@@ MN>&95JZ3GA1<+,)<=OO%^DEC[/ ;&'^!)J9/9>Y)C3+Y,12E?H*)JRIO(^' M_69&U<)!>SN/+9Y%Y['G2\YC]TDP$.SN$Z**I=Q+Y9XOE%+V0*J9QQP-4NT+ ML\<-P#G'7D"PJ& 3;^PV]Y^3\"XWX^4C+&^,P(<<0"-S?, /6B1[!%<(>G&? M^@X6&%''P4^TL3/>W>U2Z:JP5--]\J@S?TPG1YU)"<^LE8/1_03I\+J4_0G! M^1.'\JM.9C>Y3VZ#^^*^XXOIPI+FJ+#YZ&BYJK#^@J;@JX1WVV' )_!NO2$= MJU1XD?VK5GU" E;OV3AJ0O&LMW)C_&G!I7'FUH9-W MNFQ'=P<>[/MT@+NP<>3"Z\403 >"3U@\PQ-(P@%,A_6HUT7%P(E,J534 4P# M P43X73 JIZ0L##W*4/Q,MX-7FSFEA:LPWEH'9[0P^=6/)7#[>=Y94_OFJWW M]5:ZUKRYJ=ZUZZ7XQS9E3X7%JJ=06R+-. I+GXZ6E!U=8-71T?J(=DWU4G%: MO11!VV<2:4F,##86J>Y?I_+/N4%L:=XK 7L!=.PS@8S,4R+9-$4G=[#/\)=E M#MZ-2SNG+/95ZK7&SWNFMF=5EOPQ^$I^'\-^3GX?@HD[<,7+1C6#N]'>\!23 M/*7%M?YPZS09W1*I]3CK+GS++:<+/HIS0'$<,.<4E;/A/X1D_HVDRO\!4$L! M A0#% @ ^X$P6:LS^_.(! /A, !( ( ! &)L M86-U+3(P,C0P.3$P+GAS9%!+ 0(4 Q0 ( /N!,%FB8'@W?P8 "H\ 6 M " ;@$ !B;&%C=2TR,#(T,#DQ,%]D968N>&UL4$L! A0# M% @ ^X$P6: XML 16 d894292d8k_htm.xml IDEA: XBRL DOCUMENT 0001840425 2024-09-10 2024-09-10 0001840425 blacu:UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member 2024-09-10 2024-09-10 0001840425 us-gaap:CommonStockMember 2024-09-10 2024-09-10 0001840425 blacu:RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member 2024-09-10 2024-09-10 0001840425 blacu:RightToReceiveOnetenth110OfOneShareOfCommonStockMember 2024-09-10 2024-09-10 false 0001840425 8-K 2024-09-10 BELLEVUE LIFE SCIENCES ACQUISITION CORP. DE 001-41390 84-5052822 10900 NE 4th Street Suite 2300 Bellevue WA 98004 (425) 635-7700 false false false false Units, each consisting of one share of common stock, one redeemable warrant and one right BLACU NASDAQ Common stock, par value $0.0001 per share BLAC NASDAQ Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share BLACW NASDAQ Right to receive one-tenth (1/10) of one share of common stock BLACR NASDAQ true false